Annual Report Template, Sample, Example and Format

In general word annual report is a comprehensive report on a company’s activities.  Annual report are intended to mainly shareholder and many other people who want to know about the company’s financial activities. So here we provide annual report template / annual report sample / annual report example / annual report format to make the topic very clear.

Annual Report Template / Sample / Example / Format

 

Director’s Report

For the year ended 31st December 2003

The Directors are pleased to present their report to the shareholders together with the audited accounts for the year ended 31 December, 2003,

Financial Results and profit Appropriations

 

Figure in

‘000 Taka
2003 2004
Net Profit Before Providing Income Tax 263,618 352,232
Less : Income Tax Expense (38,975) (20,552)
Net Profit After Tax 224,643 341,680
Add : Profit Brought Forward From Previous Year 1,421,656 1,294,000
Profit Available for Appropriation 1,646,299 1,635,680
Recommended for Appropriation:
Transfer to Tax-Holiday Reserve (91,3562) (125,524)
Proposed Dividend   ; (101,775) (88,500)
Dividend Distribution Tax (5,089)
(198,226) (214,024)
Un-appropriated Profit Carried Forward 1,448,073) 1,421,656

Dividend

 The Board of Directors has recommended .10% cash dividend and 10% stock dividend (Bonus Share) for your approval for the year ended 31st December, 2003.

Directors

Mr. Salman F Rahman, Director of the company retires by rotation as per Articles 126 and 127 of the Articles of Association of the Company and being eligible, offer himself for reelection.

Mr. Iqbla Ahmed (Nominee of Bangladesh Export Import Company Limited) and Mr. O.K. Chowdhury and Mr. A.B. Siddiqur Rahman (Nominees of Beximco Holdings Limited) Directors of the company, retire by rotation as per Articles 126 and 127 of the Articles of Association of the Company ,and being eligible, offer themselves for re-election.

Auditors

The Directors hereby report that the existing Auditors, M/S A.U. Russel & Co. Chartered Accountants, National Plaza. (6th Floor), 1/C Free School Street, Sonargaon Road, Dhaka-1205 who were appointed as Auditors of the company in” the Twenty seventh Annual General Meeting of the Company have carried out the audit for the year ended 31 December 2003.

M/S M.J. Abeding & Co., Chartered Accountants, National Plaza (6th Floor), 1/C Free School Street, Sonargaon Road, Dhaka-1205, the Auditors of the Company retire at this meeting and have expressed their willingness to continue in office for the year 2004

On behalf of the Board

ASF Rahman Chairman

Dhaka
27 April, 2004

annual_report_template_sample_example_and_format

BEXIMCO   PHARMACEUTICALS   LIMITED
Report of Auditors to the Shareholders

We have audited the accompanying Financial Statements of Beximco Pharmaceuticals Limited consisting of a Balance Sheet, a Profit and Loss Account and the Statement of Changes in Equity and Cash Flows as well as-the Notes to the financial statements for the year from January 1 to December 31, 2003. The preparation and the content of the financial statements according to International Accounting Standards are the responsibility of the company’s board of directors.

In our opinion, based on our audit, the financial statements referred to above give a true and fair view of the financial position, the results of operations and cash flows of the company, in all material respects, for the year referred to above, in accordance with the Companies Act 1994, the Securities and Exchange Rules 1987 and the International Accounting Standards adopted by the ICAB.

We also report that:

  • We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;
  • In our opinion, proper books of accounts as required by law have been kept by the company so far as it appeared from our examination of those books;
  • The Company’s Balance Sheet and Profit and Loss Account dealt with by this report are in agreement with the books of accounts  and
  • The expenditures incurred were for the purpose of the Company’s business.

M.J. ABEDIN & CO.
Chartered Accountants
National Plaza (6th Floor)
1/G, Sonargaon Road
Dhaka-1205

27 April, 2004

SQUARE PHARMACEUTICAL LTD.

Directors’ Reports
TO THE SHAREHOLDERS FOR THE YEAR 2003-2004
REFERRAL:

In terms of provisions of Section 184 of the Companies Act 1994, Rule Inland the schedule there under) of the Securities and Exchange Rules 1987 and IAS- I (International Accounting Standards-l) codes as adopted by the institute of Chartered Accountants of Bangladesh (ICAB), it is the pleasure of the Board of Directors to submit its Report to the Shareholders for the year ended 31 March 2004 in the following paragraphs:

1. economic 7-environmental situation:

The year under review has undergone yet another period of turbulent law and order situation with increased number of hartal and political agitation’s causing great losses to the economy, especially to the corporate sector. Though export earnings increased and recovered the losses sustained during the previous year, the public expenditure through ADP shrunk as the revised budgetary allocation was reduced substantially as a result of which GDP growth rate fell short of the target of 5.5%. The foreign exchange reserve increased primarily due to increase remittances from the expatriate Bangladeshis. However, the foreign portfolio and direct investment flow was almost non-existent despite v various promotional steps by the government and the private sector including lowering of bank rate and re-lending rate by the Banks. As regards the capital, market situation, there were a few IPOS other than those of Banks which were oversubscribed by number of times and the share price index moved up the ladder along with increased volume of trade and capitalization. The process of dematerializing of securities by CDBL is also encouraging for investors and the capital market.

2. PHARMACEUTICAL SECTOR:

The pharmaceuticals sector attained a lower growth of 5SQ% only during the year 2003 as against 10.18% during the previous year and against 22.46% during the earlier year as per IMS Report. The wide variance in the growth rate of national pharma market may be attributed to various factors such as public expenditure on health care, natural calamities including floods, cyclones, epidemical diseases & agro-crop harvest. The national pharma market growth and that the Company during the past few years is given below:

 

Year

National Market Growth Rate

Company’s Growth Rate

1999 0.89% 9.60%
2000 27.79% 29.95%
2001 22.46% 22.70%
2002 10.18% 11.70%
2003 5.90% 15.91%

The statistics given above prove that the Company has been performing at a higher rate than that of the national growth rate of pharmaceutical market ensuring continued leading position in the market.

3. OPERATIONS REVIEW:

(1) PHARMA UNIT AT PABNA:

The Company continued to upgrade qualitative capacity of Pabna Unit and about 90% of output was produced in this plant. The company made a capital expenditure of Tk. 77.00 million at Pabna Plant divided as follows:

  • (a)  Land                                                                                3.20
  • (b)  Building/Civil Works                                               15.17
  • (C) Plant Machinery                                                         29.08
  • (d) Other Assets                                                                 29.55
  • Total Tk. (Million)                                                             77.00

As against the above capital expenditure during the year under review, an amount of Tk. 46.53 million was invested in Pabna plant during the previous year. All Chose investments have helped to meet the increased demand- both qualitatively and quantitatively.

 (2) CHEMICAL PLANT

The operations of the chemical Plant (at Pabna) during the last five (5) years are presented hereunder:-

Years No. of Production Own Use Sales Own Turnover
Products (M. Tons) (M. Tons) (M. Ton) Use% (Mi I ion Taka)
1999-00 6 192 63.08 128.92 32.85% 192.78
2000-01 7 227 82,39 -144.61 36.30% 209.08
2001-02 7, 201 85.30 115.70 42.44% 301.39
2002-03 9 219 89.34 129.66 40.79% 291.67
2003-04 9 242 129.71 112.29 53.59 321.73

The production/capacity utilization has been varying depending on the nature of demand from the formulation unit and market operators.

3. DHAKA PLANT:

As reported earlier the State-of-Art Plant located at Kaliakoir, which commenced commercial operations with effect from 7th April 2002 with capital assets at Tk. 2,061,671,687 as on that date and Capitalized  for charging depreciation as allowed by Taz Laws has been gradually increasing its capacity utilization arid by end of the accounting year, reached the level of as hereunder.

(Quantity in thousands)

SI. No

Particulars

Unit

Capacity

Actual Outpour

Capacity Utilization

Product Number 2002-03 2003-04 2002-03 2003-04
1 Tablets pcs 836,256 85,269 417,352 10.20% 49.91%.
2. Capsules pcs 202,320 17,247 108,307 8.52% 53.53%

 (4) PRODUCT DEVELOPMENT:

In order to meet the requirements by the WTO regulations and heavy competition from 2016 resulting from globalization/ liberalization of trade and strict compliance of Intellectual Property Rights, the Company has been trying to develop new products every year.

The following table which is mention in below table shows the position of existing and new products introduced during the year 2003-2004:

SI. No Products Categories Position as on 31-03-03 Added during the year Total (31-03-04)
1 Tablets 105 14 110
2 Capsules 35 5 40
3 Liquids Indictable 26 2 40
4 Injectables 32 1 33
5 ENT Preparation & Other 25 28
6 Opthal Preparations & Others 7 7
7 Dm Sump Suppository 14 14
8 Suppository 3
9 Inhaler L 4
10 Basic Chemicals 9 9
11 Tablet, Powder, Liquid, Injectable- Agro Vet 19 19
Total 279 25 304

The new products have been well received by the medical profession and the market. Filwel Gold Tablet is a multivitamin and multimineral product, which “Truly ensures 32 vitamins and minerals”. It is a best match option for all types of vitamin and mineral deficient patients (except children) to fulfill the deficiency. It is presented in a container with child lock cap to protect misuse by the children.

Filwel Cold tablet container has silica gel to ensure moisture protection. Filwel Gold is the same formulation of worldwide established brand Centrum.

(5) OUTPUT/CAPACITY UTILIZATION:

The overall capacity utilization of the- plant operation continued to improve during the year as shown hereunder:

SI. No. Product Categories Units Production in thousand Increase Decrease Capacity Utilization
2003-04 2002-03 2003-04 2002-03
1 Tablets pcs 2,115,330 1,829,089 16 122% 105%
2 Capsules pcs 344,100 295,23’4 17 112% 96%
3 Liquids Bottles 23,485 21,210 11 112% •1 18%
4 Injectables (Vials & Ampoules’ pcs 17,391 13,325 31 97% 74%
5 ENT Preparations & Others Phials 10,669 8,651 23 237% 192%
6 Opthal Preparations & Others Phials 958 1,083 (11) 160% 181%
7 Dry Syrup Bottles 3,639 4,048 (10) 152% 169%
8 Suppository pcs 2,729 1,671 63 45% 28%
9 Inhalers Can 373 298  25 41% 50%
10 Basic Chemicals Kg 242 219 -11 71% 64%
11 Tablet-AgroVet pcs 1,463 1,262 16 77% 67%
12 Power-AgroVet Cm 8,758 34,911 (75) 66% 189%
13 Injection-AgroVet pcs 1.601 1,203 33 36% 27%
14 Liquides-AgroVet Bottles 68 17 300 6% 2%

Capacity utilization during 2003-04 still remained at lower due to start-up of the new plant at Kaliakoir with huge operative capacity and lower initial production. The overall combined capacity mutilation of all the three plants (including chemical plant) would gradually increase over the coming years.

(6) QUALITY CONTROL:

The company places total emphasis on maintaining and improving of quality of its products as “life science biology following strictly laid down criteria at every level of production and handling. The Company also follow-up withdrawals from market of all expiry dated products through’ close ‘inspection and surveillance. The quality control facilities include a high quality standard Laboratory Building, Computerized Equipments and tools and a team of highly qualified /trained research personnel who are bent upon on unstinted attainment as ethical and moral objective. We are proud of them.

(7) TECHNOLOGY:

The company is endeavoring to upgrade and adopt new technology in production; quality control, distribution and administration of its products to patients. During the year (2003-2004) the Company invested an amount of Tk. 9,524,491 in improving its Laboratory.

(8) EXPORT:

The Company is continuously pressing hard for expanding its export sales/ during the year under review, the exports amounted to Tk. 59.95 million as against Tk. 35.08 million in previous years, a 71% increase. The exports are expected to rise in the coming years.

(9) SUBSIDIARY OPERATION:

Square Spinnings Ltd.

The Company (SPL) holds 98% equity in Square Spinning’s Ltd. which .has a production capacity of 7,470,360 kg per annum (based on NE 20s) and commenced commercial production on 10 January 2001. The Company’s operation results from first year with comparative position of performance over the years 2001. The Company’s operation results from first year with comparative position of performance over the, years (2001 -2003) is given below:

                                                                    2001                   2002                   2003

  • Production (kg)                       61, 16,123          76, 19,072        87, 28,975
  • Sales Revenue (Tk.)               703,524,368    768,539,068    883,390,854
  • Gross Profit (Tk.)                    162,802,597     184,610,026    191,103,372
  • Net Profit (Tk.)                        71,626,873        73,403,013      91,306,429
  • Gross Margin                           23.14%                  24.02%               21.63%
  • Net Margin                               10.18%                  9.55%                  10.34%
  • EPS (Tk.)                                    71.63                     73.40                  91.31
  • NAV (Tk.)                                  171.63                   245.03               336.34

Capacity Utilization (SSL):

The capacity utilization and operating profitability show improvement resulting in increase in Net Asset Value to shareholders. However, despite enough earnings for every share, the management has not yet considered it appropriate and opportune to declare dividend’s fund generated from operations by profit and depreciation have been largely utilized for repayment of loans and liabilities which, as a result, have been substantially reduced/restructured with redemption of external debt risks. The Net Asset Value has thereby been enhanced to the benefit of the shareholders.

 The following changes took place in the position as on 31-12-2003 and 31-03-2004 and 31-03-2004 being the dates of closure of accounting year for Squae Spinnings Ltd. and the Company (SPL) respectively:

 (Taka)

SI. No Particulars Position as on 31-12-2003 Position as on 31-03-2004
1 Fixed Asset Cost of Square Spinnings Ltd. 716,943,502 717,917,066
2 Investment by Square Pharmaceuticals Ltd.* Share Capital*Short Term Loan*Medium Term Loan 98,000,000 188,161,117 150,000,000 98,000,00 141,198,731 120,000,000

 Directors’ Report on the Company together with Audited Accounts containing Balance Sheet, profit & Loss Statement and Cash Flow Statement and Auditors Report thereon are included herein.

(10)    LONG TERM INVESTMENT (OTHER THAN SUBSIDIARY):

The above investments include minority investments in ordinary shares/advance as Share Money Deposit in 7(seven) different companies as follows:

(1) Square Textiles Ltd. (STXL):

As on 31–03-04 investment in this Company (after listing with Stock Exchanges) ‘stands at Tk. 125,000,000 for 12,500,000 ordinary shares of Tk. 10. each (at cost) and the market value as on 31st March, 2004 stood at Tk. 547,500,000 (at Tk. 43,80 per share) showing 338% appreciation. The Company is in full operation and declared cash dividend at the rate of 30% and stock dividend at the rate of 10% (10:1B) for the year 2003 as against 32% cash dividend only for the previous year. SPL hold 49.62% shares-of the Company.

(2) Continental Hospital Ltd. (CHL)

The Company (SPL) holds 120,000 shares of Tk 100 each amounting to Tk 12,000,000 out of the paid -up capital of Tk 223,185,300. The Company has a seat on the Board of Directors. The Company has not commenced operation as is considered stuck up due to management and fund problems. Since the Company is not a listed one, it does not have any ready market value. SPL holds 5.38% shares of the Company.

 (3) National Housing Finance and Investment Ltd. (NHFIL):

The Company (SPL) holds 200,000 ordinary shares of Tk. 100 each for Tk. 20,000,000 out of total Tk. 400,000,000 (5%). The Company has a seat on the board. NHFIL is in operation since 1999 and has declared interim dividends as 10% during the year 2003 as against 12/5% during the previous year.

 (4) Central Depository Bangladesh Ltd. (CDBL):

SPL has paid for 10 (ten) shares of Tk. 1, 000, 000, 00 each in the Capital of CDBL which has been formed under the Central Depository Act 1999 for fungible and dematerialized share holding/trading which will do away with the physical possession of scrip’s and primarily prevent fraudulent/fake share trading as a result of which corporate expenditure on share office will substantially be saved. CDBL commenced its service w.e.f. July 2003. So far 15’companies have joined CDBL. The shares are not listed and therefore the market value cannot be assessed. The Company has a seat on the Board of CDBL as its Chairman.

(5) Square Hospitals Ltd. (SHL)

SPL holds, 5,700 Ordinary Shares of Tk. 1,000/- each including 2,000 Shares with premium 6Tk. 5,50Q/- each. The project originally conceived as a Five-Star Hotel at Panthapath, Dhaka is now being developed as a modern hospital with 300 beds and diversified medical services with special emphasis on cardio-vascular remedies.’ SHL has already entered into a Management Agreement with Bumrungrad Hospital of Bangkok. The project implementation is expected to be completed by end of 2005. Meanwhile partial services would be started by mid 2005. SPL hold 14.04% of SHL. Since the Company is not a public and listed on the market value of investment cannot be assessed now.

 (6) Square Knit Fabrics Ltd. (SKFL):

Due to changes in equity holdings by SPL (from 84% to 48.84%) the position, of SKFI has changed from subsidiary to investment category. The Company started production from early 2002 and is trying to overcome initial teething problems as well as problems arising from international issues. The Management is keeping a close watch on its operations and would continue to endeavor for attaining profitable results; the Company did not declare any dividend for sustenance of losses. SPL now holds 1,260,000 ordinary shares of Tk 100 each which is 48.84%. The Company is not a public/listed one and-hence the market value cannot be readily assessed.

(7)  Square Fashions Ltd. (SFL):

SPL now hold 252,000 Shares of Tk. 100 each (48.46%) in the-capital of SFL. The Company has not declared any dividend due to sustenance of losses. Since the Company is not a public/listed one, the market value cannot be assessed readily.

(11)    INVESTMENT IN MARKETABLE SECURITIES:

Pioneer Insurance Company Ltd. (PICL):

SPL acquired 150,000 Ordinary Shares of Tk. 100 each at Tk. 135 each including premium’ of Tk. 35 each by way of Pre IPO placement, this constitutes 10% of the issued capital of PICL. The Company (PICL) has declared dividends at the rate of 1 2% for the year 2003 as against 15% for the year 2002. The shares are listed and currently quoting at about Tk. 260 per share indicating about 92% capital gains.

(12)    FINANCIAL RESULTS:

The operating financial results of the Company for the year 2003-2004 as compared do previous year are summarized hereunder:

Particular                                               2002-2003                   2003-2004                   (%) increase
Taka                                  Taka                                  Decrease

  • Gross Turnover                      4,729,742,876            5,482,087,920             15.91%
  • Net-Turnover                          4,065,850,882.           4,721,551,742              16.13%
  • Gross Profit                               1,466,282,444             1,906,592,013              30.03%
  • Net Profit (BT)                          929,604,086                1,151,636,314               23.88%
  • Provision for Taxation         164,719,297                 1&1,592,77T                 10.24%
  • Net Profit (AT)                         764,884,789                 970,043,543                26.82%
  • Cross Margin (NetT.O)          36.07%                            40.38%
  • Net Margin (BT)                       22.86%                             24.39%
  • Net Margin (AT)                      18.81%                              20.55%
  • Earnings per share (EPS) (Tk.)    212.47                     269.46
  • Consolidated Earnings per share (EPS) 205.51       279.95 (Tk.)

It may be observed that the Gross Turnover increased by 15.91% during the year under review over the previous year of 11.70% and the Gross Profit increased by 30.03% primarily due to decrease in cost of goods sold from 54.96% in the previous year to 51.35% during the current year. This was again due to decrease in cost of raw materials consumed from 36.03% in previous year to 31.80% during the current year The incidences of packing materials & Factory overhead also decreased marginally with positive impact on gross profit, though operating & financial expenses marginally increased, net profit margin (BT) increased to 24.39% from 22.86% of previous year.

The Earning per Share of Tk. 269.46 is based on increased outstanding 3, 6000,000 shares of Tk. 100 each. However, if the original issued capital for cash at the time of IPO is considered, .the ESP would stand at Tk. 48,502 in 2003-2004 as against Tk. 37,972 in 2001-2002 and Tk. 38, 244 in 2002-2003.

(13)    APPROPRIATION OF PROFIT:

Considering the need for growing expansion and diversification of operations, increasing cost of external sources of funds, the Board of Directors have proposed and recommended for appropriation as follows:

A Un-appropriated Profit from previous 479,082,130
B Net Profit for the Year (2003-2004) 970,043,543
C Total funds available for appropriation 1,449,T25,673
D Appropriation Proposed:
1 Tax Holiday Reserve 193,058,076
2 Cash Dividend @ Tk. 70 per Share 252,000,000
3 Issuance of 720,000 Bonus Shares(Stock Dividend) at the rate of one share for  every five shares held 72,000,000
E Net inappropriate Profit 542,258,076906,867,597

(14)    DECLARATION OF DIVIDEND:

In the line of proposed appropriation of profit, the Board of Directors proposes arid recommends for declaration of Cash Dividend at the rate of Tk. 70.00 per share for the year 2003-2004 this will involve an amount of Tk. 252 million, the Board-also recommended for declaration of Stock Dividend (Bonus Shares) at the rate of one share for every five shares held. This will need issuance of 720,000 ordinary shares of Tk. 100 each-with appropriation of Tk. 72,000,000 to Capital Account.

(15)  SHARE HOLDERS BENEFIT:

Investment in the company’s stock has substantially benefited the investors since IPO, listing of the shares. An evaluation of shareholder’s benefit since IPO in 1994-95 may be presented as hereunder for a subscriber of 100 shares of Tk. 100 each at Tk. 900 per share:

SI. Accounting Rate of Cash Bonus Shares Cash Present Worth at 1 2.5%
Years Dividend Issued Distribution as Discounted
Dividend
Years Amount
1 1994-95 32.00 3,200 9 9,237
2 1995-96 32.50 25 4,062 1.0,422
3 1996-97 35.00 4,375 7 9,978
4 1997-98 45.00 5,625 6 11,403
5 1998-99 55.00 6,875 5 12,388
6 1990-00 65.00 8,125 4 13,014
7 2000-01 70.00 8,750 3 12,458
8 2001-02 75.00 25 9,375 2 11,865
9 2002-03 70.00 30 10,500 1 11,812
10 2003-04 70.00 36 12,600 0 12,600
Total 116 73,487 115,177
4 Without At 12.50%
Discounting Discounted
Present Market value of 1 1 6 shares (Bonus) at Tk.3,’484/Share 404,144 404,144
Dividend Distribution 73,487 115,177
Present VAlue of 275 shares of Square Textiles Ltd. at Tk.56/Share 15,400 15,400
Dividend of Square Textiles Ltd. 2,300 2,606
Capital Cain from 100 shares of SPL (Tk. 3,484-900) 258,400 258,400
Total (Tk.) 753,731 795,727

(16)    CONSOLIDATION OF ACCOUNTS:

In terms of SEC regulations, the company has consolidated the Accounts following the codes of International Accounting Standard-27 (AIS-27) reflecting shareholders gross benefits/value of investments.

 4. HUMAN RESOURCES DEVELOPMENT:

In order to improve productivity of human input, the Company continuously, provides formal and informal training to the employees at every echelon of operation and management. During the year under review 1,301 persons received in-house/in operation/on the job training at home and abroad which will ultimately make great contribution to the Company’s profitability as well their own remuneration in due course.

5. ENVIRONMENTAL ROLE:

The Company maintains a high standard of pollution free environment as per GMP Regulations /WHO standards/Government laws.

 6.  CONTRIBUTION TO NATIONAL EXCHEQUER:

The company contributed an-amount of Tk. 1,102,617,542 (including Tk. 10,984,279 as contribution towards machinery & spare parts imports to National exchequer as against Tk. 978-032.738 in the previous year indicating an increase of 12.74%. The contribution constituted 23, 35% of the sales revenue (net) in 2003-2004 as against 24.05% in the previous year (2002-2003).

7. ELECTION OF DIRECTORS:

Dr. Kazi Harunar Rashid and Mrs. Jahanarda Chowdhury retire as per articles 99 and 100 of the Articles of Association of the company and being eligible, have offered themselves for re-election.

 8. APPOINTMENT OF AUDITORS:

M/s. Chowdhury bhattacharjee & Co. Chartered .Accountants. Auditors of the company, retire at this annual general meeting and being eligible offer themselves for appointment as Auditors for the year 2004-2005 and refixation of heir: remuneration.

9.  MANAGEMENT APPRECIATION:

The Board of Directors record with deep appreciation the contribution made and support & CO-operation given by the Officers, Staff, Workers, Customers, Creditors, Banks, Insurance Companies, Utility Providers, SEC, DSE, CSE, VCDBL arid the Government in particular and look forward to the global role of the Company.

Samson H Chowdhury
Chairman

Related Content of Report Writing:

6 comments for “Annual Report Template, Sample, Example and Format

  1. Edward Y. Kander
    May 5, 2014 at 7:38 pm

    This is one of the best annual report because this is clear and explanatory.

  2. Rohan
    October 6, 2016 at 3:20 pm

    This types of content is little bit rare in web thanks for sharing this useful content.

  3. kam wan
    October 13, 2016 at 3:16 pm

    It helps me to prepare my company’s annual report. Thanks

  4. Marlin
    March 21, 2017 at 12:15 am

    WOW just what I was looking for. Thanks for the great info

  5. dial
    November 18, 2017 at 2:53 am

    Appreciate this post. Let me try it out.

  6. Tahir
    July 3, 2019 at 2:25 am

    I blog quite often and I really appreciate your content. This
    great article has truly peaked my interest. I am
    going to take a note of your site and keep checking for new
    details about once per week. I opted in for your RSS feed too.

Leave a Reply

Your email address will not be published. Required fields are marked *